Dados B3 › SUZB3 × VALE3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | SUZB3 | VALE3 | year |
|---|---|---|---|
| ROE | 35.2% | 7.1% | 2025 |
| ROIC | 6.2% | 6.6%! | 2025 |
| ROA | 8.0% | 2.4% | 2025 |
| Gross margin | 32.4% | 35.0% | 2025 |
| EBIT margin | 21.2% | 15.0% | 2025 |
| Net margin | 26.8% | 5.5% | 2025 |
| Net debt/EBITDA | 3.18x | 1.25x | 2025 |
| Current ratio | 3.19x | 1.15x | 2025 |
| Revenue growth (1y) | 5.7% | 3.7% | 2025 |
| Revenue growth (5y CAGR) | 10.5% | 0.7% | 2025 |
| Piotroski F-Score | 8/9 | 6/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | SUZB3 | VALE3 | year |
|---|---|---|---|
| P/E | 4.71x | 24.49x | 2025 |
| P/B | 1.44x | 1.84x | 2025 |
| EV/EBITDA | 6.05x | 8.12x | 2025 |
| FCF yield | 21.4% | 4.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:49 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it